Source: Virtual Congress 2021 – Lung cancer grand round



Rating:

Share or cite this content

Citations should be made in the following way:
S. Tsim (Glasgow (Glasgow), United Kingdom). Combination immunotherapy in mesothelioma: managing expectations and new toxicities. Virtual Congress 2021 – Lung cancer grand round

Member's Comments

No comment yet.

Related content which might interest you: Malignant mesothelioma: new treatment advances, including targeted therapies Source: Virtual Congress 2021 – Diagnostic and therapeutic advances in mesothelioma care Year: 2021 Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis? Source: Eur Respir J, 51 (1) 1701737; 10.1183/13993003.01737-2017 Year: 2018 Combination therapy in the era of immunotherapy Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Optimisation of chemotherapy in the era of immunotherapy Source: Eur Respir J, 52 (4) 1801698; 10.1183/13993003.01698-2018 Year: 2018 New molecular-directed therapies for mesothelioma: have there been any advances? Source: International Congress 2014 – Mesothelioma: a never-ending story Year: 2014 Therapeutic options for sarcoidosis: old and new Source: Annual Congress 2005 - PG15 - Therapeutic options for interstitial lung diseases in 2005 Year: 2005 Multimodal therapy in mesothelioma: which modalities are available and useful and how to combine them Source: International Congress 2014 – Mesothelioma: a never-ending story Year: 2014 Malignant pleural mesothelioma: new treatments, new hopes? Source: Eur Respir J , 49 (3) 1700319; DOI: 10.1183/13993003.00319-2017 Year: 2017 Systemic therapies: optimising the sequences of chemotherapies, targeted therapies and immunotherapies Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy Year: 2017 Immunotherapy for malignant pleural mesothelioma: ready for clinical practice? Source: International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies? Year: 2016 Rationale and targets of immunotherapy in thoracic malignancies Source: International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies? Year: 2016 Immunotherapy: a new standard of care in thoracic malignancies? Source: Eur Respir J, 51 (2) 1702072; 10.1183/13993003.02072-2017 Year: 2018 Bronchiectasis: new therapies and perspectives Source: International Congress 2018 – Bronchiectasis: new insights in diagnosis and treatment Year: 2018 Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer Source: Eur Respir Rev 2014; 23: 30-35 Year: 2014 Challenges and limitations of individualised therapy Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 The side-effects of TB therapy: myth and reality Source: Annual Congress 2005 - PG10 - The management of tuberculosis: tradition and novelties Year: 2005 Novel aspects in lung cancer pathology: how does it help for selecting chemotherapy? Source: Annual Congress 2010 - PG4 Core Curriculum Postgraduate Course: Pathology for the clinician Year: 2010